Evaluation of Commercial Assays for Single-Point Diagnosis of Pertussis in the US | Zendy

Lucia C. Pawloski | Zendy; Brian D. Plikaytis | Zendy; Monte D. Martin | Zendy; Stacey W. Martin | Zendy; Harry E. Prince | Zendy; Mary Lapé-Nixon | Zendy; M. Lucia Tondella | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Commercial Assays for Single-Point Diagnosis of Pertussis in the US

Author(s) -

Lucia C. Pawloski,

Brian D. Plikaytis,

Monte D. Martin,

Stacey W. Martin,

Harry E. Prince,

Mary Lapé-Nixon,

M. Lucia Tondella

Publication year - 2016

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piw035

Subject(s) - medicine , pertussis toxin , serology , concordance , antibody , pertussis vaccine , immunoglobulin g , immunology , g protein , receptor , immunization

Pertussis serodiagnosis is increasingly being used in the United States despite the lack of a US Food and Drug Administration-approved, commercially available assay. To better understand the utility of these assays in diagnosing pertussis, serology assays were evaluated for analytical parameters and clinical accuracy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research